UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Gut, 2020-03, Vol.69 (3), p.551

2020

Link zum Volltext

Verfügbarkeit prüfen

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

International journal of molecular sciences, 2022-02, Vol.23 (5), p.2668

2022

Link zum Volltext

Verfügbarkeit prüfen

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

Journal of hepatology, 2020-10, Vol.73 (4), p.757-770

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Hepatology (Baltimore, Md.), 2018-04, Vol.67 (4), p.1270-1283

2018

Link zum Volltext

Verfügbarkeit prüfen

Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury

Hepatology (Baltimore, Md.), 2016-11, Vol.64 (5), p.1667-1682

2016

Link zum Volltext

Verfügbarkeit prüfen

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

PloS one, 2017-09, Vol.12 (9), p.e0184694-e0184694

2017

Link zum Volltext

Verfügbarkeit prüfen

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

International journal of molecular sciences, 2023-03, Vol.24 (6), p.5295

2023

Link zum Volltext

Verfügbarkeit prüfen

Monocyte dysregulation: consequences for hepatic infections

Seminars in immunopathology, 2021-08, Vol.43 (4), p.493-506

2021

Link zum Volltext

Verfügbarkeit prüfen

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

International journal of molecular sciences, 2022-06, Vol.23 (12), p.6696

2022

Link zum Volltext

Verfügbarkeit prüfen

CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients

PloS one, 2021-04, Vol.16 (4), p.e0250321-e0250321

2021

Link zum Volltext

Verfügbarkeit prüfen

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis

Journal of clinical medicine, 2020-04, Vol.9 (4), p.1140

2020

Link zum Volltext

Verfügbarkeit prüfen

Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis

Liver international, 2024-02, Vol.44 (2), p.275-278

2024

Link zum Volltext

Verfügbarkeit prüfen

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Expert opinion on investigational drugs, 2023-06, Vol.32 (6), p.451-461

2023

Link zum Volltext

Verfügbarkeit prüfen

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Alimentary pharmacology & therapeutics, 2020-10, Vol.52 (8), p.1412-1413

2020

Link zum Volltext

Verfügbarkeit prüfen

Repair macrophages in acute liver failure

Gut, 2018-02, Vol.67 (2), p.202

2018

Link zum Volltext

Verfügbarkeit prüfen

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Journal of clinical medicine, 2022-04, Vol.11 (9), p.2479

2022

Link zum Volltext

Verfügbarkeit prüfen

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

Journal of global antimicrobial resistance., 2023-03, Vol.32, p.44-47

2023

Link zum Volltext

Verfügbarkeit prüfen

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Journal of hepatology, 2023-08, Vol.79 (2), p.552-566

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients

Diagnostics (Basel), 2020-11, Vol.10 (11), p.990

2020

Link zum Volltext

Verfügbarkeit prüfen

Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)

Expert opinion on investigational drugs, 2023-06

2023

Link zum Volltext

Verfügbarkeit prüfen

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients

Diagnostics (Basel), 2021-12, Vol.12 (1), p.62

2021

Link zum Volltext

Verfügbarkeit prüfen

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

Expert review of endocrinology & metabolism, 2022-09, Vol.17 (5), p.425-434

2022

Link zum Volltext

Verfügbarkeit prüfen

PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis

Journal of hepatology, 2019-04, Vol.70 (1), p.e8-e9

2019

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S13

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(27)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

Monocyte dysregulation: consequences for hepatic infections

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis

Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Repair macrophages in acute liver failure

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients

Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

Acquisition of epithelial plasticity in human chronic liver disease

PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis

Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Suchergebnisse filtern